fbpx
QQQ
+ 0.00
339.34
+ 0%
DIA
+ 0.00
341.24
+ 0%
SPY
+ 0.00
416.09
+ 0%
TLT
+ 0.00
139.78
+ 0%
GLD
+ 0.00
168.12
+ 0%

A Look At PharmaCielo's High-THC Cultivation Deal In Colombia

July 13, 2020 3:05 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
A Look At PharmaCielo's High-THC Cultivation Deal In Colombia

Cannabis producer PharmaCielo (TSXV:PCLO) (OTC:PCLOF) has hit another important milestone in its quest to become a global supplier of high-grade medicinal cannabis extracts.

Last week, the Canadian-Colombian company secured a government authorization to cultivate and produce over 11 tons of high-THC dry flower for extract processing and export in 2020.

PharmaCielo confirmed that both the Colombian Ministries of Justice and Health granted the company the required authorizations to commence commercial cultivation of THC-dominant dry-flower for extract production, designated for export to the German market.

In a statement to Benzinga, David Attard, CEO of PharmaCielo said that “the government’s authorization for commercial grow and production for export of high-THC extracts adds significant depth to our medicinal cannabis product portfolio. It aligns with our growth and sales strategy and enables greater flexibility to meet current and future B2B customer needs for specific formulations at high volumes.”

To date, PharmaCielo holds 30 proprietary strains, registered in the Colombian national cultivar, including some unique high-THC strains. PharmaCielo’s proprietary cultivars are developed through extensive experimentation with an even larger range of landrace strains, of which 186 are held in the proprietary seed bank (fuente semillera) for medicinal propagation.

Courtesy photo.